# Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)

> **NCT01116804** · PHASE1 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 36 (actual)

## Conditions studied

- Primary Liver Cancer

## Interventions

- **PROCEDURE:** MRI of the liver before start of treatment
- **PROCEDURE:** MRI after treatment
- **PROCEDURE:** PET-scan before treatment start
- **PROCEDURE:** PET scan after treatment

## Key facts

- **NCT ID:** NCT01116804
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-16
- **Primary completion:** 2020-01-20
- **Final completion:** 2020-01-20
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01116804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01116804, "Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01116804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*